SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Perspectives in Vascular Surgery and Endovascular Therapy
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mozes, G.
Right arrow Articles by Gloviczki, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mozes, G.
Right arrow Articles by Gloviczki, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Adjuvant Therapy in Lower Extremity Revascularization: Prevention of Early and Intermediate Failures

Geza Mozes

Division of Vascular Surgery, Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, USA

Peter Gloviczki

Division of Vascular Surgery, Gonda Vascular Center, Mayo Clinic, Rochester, Minnesota, USA

Open surgical or endovascular revascularization of the lower extremity is not always successful. Early and intermediate-term failures of vascular grafts, stents, and stent grafts occur due to technical mistakes, thrombosis, or intimal hyperplasia. The outcome of lower extremity revascu larization can be improved by adjuvant antithrombotic treatment (antiplatelet drugs, anticoagulation) and by antiproliferative therapy such as drugs, brachytherapy, or gene therapy. Adjuvant drug therapy can be sys temic (oral or parenteral) or local (direct injection or placement of drug-elut ing grafts or stents). Systemic drug therapy may carry the additional benefit of preventing cardiovascular events, such as stroke or myocardial infarction. Unfortunately, it can also be associated with serious, mainly hemorrhagic, adverse effects. We review the English-language literature of antithrombotic and antiproliferative adjuvant therapies in the prevention of early and inter mediate failures following lower extremity revascularizations.

Key Words: revascularization • antithrombotic treatment • antiproliferative therapy • brachytherapy • adjuvant drug therapy

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 15, No. 2, 161-180 (2002)
DOI: 10.1177/153100350201500211
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement